Individualized surgery for early gastric cancer guided by sentinel node biopsy

Ichikura, Takashi; Chochi, Kentaro; Sugasawa, Hidekazu; Yaguchi, Yoshihisa; Sakamoto, Naoko; Takahata, Risa; Kosuda, Shigeru; Mochizuki, Hidetaka

doi:10.1016/j.surg.2005.09.005

Cited by 56 publications

(54 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ideal lymphadenectomy for gastric cancer should accurately stage the extent of disease, predict prognosis, and have the potential to improve survival. The rationale for SLN mapping in gastric cancer is twofold: to learn about the extent of the disease (lymph node involvement), and to try to assess the degree to which SLN mapping might aid in the decision-making process regarding the type of gastrectomy to be performedlimited or extended [24]. This question has been a matter of debate for years, as Western literature claims no superiority of an extended lymph node dissection and attributes the extent of this dissection to the added morbidity and mortality [25].…”

Section: Discussionmentioning

confidence: 99%

The accuracy of sentinel node mapping according to T stage in patients with gastric cancer

et al. 2010

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

The accuracy of sentinel node mapping according to T stage in patients with gastric cancer

et al. 2010

View full text Add to dashboard Cite

“…Assessment of SLN status to guide surgical planning is the standard of care in breast cancer and melanoma, and is being evaluated in other forms of human cancer [18][19][20]. There is also interest in SLN mapping in patients with urinary bladder cancer [11][12][13].…”

Section: Discussionmentioning

confidence: 99%

Sentinel Lymph Node Mapping of Invasive Urinary Bladder Cancer in Animal Models Using Invisible Light

Knapp¹,

Adams²,

DeGrand

et al. 2007

European Urology

View full text Add to dashboard Cite

Objectives-With conventional methodology, sentinel lymph node (SLN) mapping of invasive urinary bladder cancer is technically challenging. This study was performed to determine the utility of invisible, near-infrared fluorescent (NIRF) light for patient-specific SLN mapping, in real time under complete image guidance.Methods-Lymphatic tracers, injection volume, NIRF excitation fluence rate, light collection of emitted fluorescence, and degree of bladder distension were systematically optimized in normal dogs and pigs. SLN mapping was then performed in pet dogs with naturally occurring invasive transitional cell carcinoma (InvTCC) of the urinary bladder, which closely mimics the human disease.Results-NIRF albumin (hydrodynamic diameter [HD], 7.4 nm) and NIRF quantum dots (15-20 nm HD) injected into the bladder wall resulted in identification of draining lymph nodes (LNs) in under 3 min. In both species, considerable variability in the lymphatic drainage was observed among individuals. Optimal SLN mapping was achieved with the use of superficial, serosal injection of NIRF tracer, with the bladder distended to an intraluminal pressure of 20-40 cm H 2 O. In dogs with InvTCC, NIRF tracers identified SLNs that were confirmed histologically to harbor metastases.Conclusions-The use of invisible NIRF light permits real-time, patient-specific identification of SLNs that drain bladder cancer. Intraluminal bladder pressure is a key parameter that needs to be controlled for optimal results. KeywordsBladder cancer; Fluorescence; Intraoperative imaging; Sentinel lymph node mapping * Corresponding author. Purdue University, Department of Veterinary Clinical Sciences, Lynn Hall of Veterinary Medicine, 625 Harrison St, West Lafayette, IN 47907-2026. Tel.765-494-9900; Fax: 765-496-1108. E-mail address: knappd@purdue.edu (D.W. Knapp). Take-home message This article describes successful use of intraoperative near-infrared light to identify sentinel lymph nodes (SLNs) draining invasive urinary bladder cancer in animals. This technology will permit studies of a new approach to identify SLNs at the time of cystectomy.Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers

show abstract

“…When injected at high enough concentrations, ICG likewise causes green "staining" of lymphatic vessels as it progresses to the draining LNs, which also become green and directly visible without the needed use of NIR fluorescence. Motomura et al [29] injected 25 mg subcutaneously for direct visualization of tumor-draining LNs in breast cancer patients, while Ichikura et al [30], Yaguchi, et al [31], and Park et al [32] likewise injected 5 -7.5 mg and 25 mg subcutaneously to visualize SLNs in gastric cancer patients. Given that both ICG and blue dyes both bind to globulin proteins within tissues, it may not be surprising that they are both avidly taken up by the lymphatics and that SLN mapping with ICG staining correlates well with standard blue dye staining [33,34].…”

Section: Sentinel Lymph Node Mappingmentioning

confidence: 99%

“…These studies suggest that for superficial tumor-draining lymph node basins, NIR fluorescence could supplant lymphoscintigraphy, which is typically performed with administration of 99m Tc radiocolloid followed by gamma camera imaging for surgical planning nuclear and gamma probe interrogation for intraoperative localization. Indeed, several studies suggest similar performance of lymphoscintigraphy and ICG fluorescence for identification of SLNs [19,30,31,37]. Although the advantages of using a non-radiative, nonspecific probe such as ICG are significant, it remains unclear whether they are great enough to warrant the replacement of the blue dye (administered at comparable doses that ICG was administered above) and/or 99m Tc radiocolloid as non-specific agents for resecting LNs for cancer staging.…”

Section: Sentinel Lymph Node Mappingmentioning

confidence: 99%

Near-Infrared Fluorescence Imaging in Humans with Indocyanine Green: A Review and Update~!2009-12-07~!2009-12-23~!2010-05-26~!

Marshall¹,

Rasmussen²,

Tan³

et al. 2010

TOSOJ

247

117

View full text Add to dashboard Cite

Near-infrared (NIR) fluorescence imaging clinical studies have been reported in the literature with six different devices that employ various doses of indocyanine green (ICG) as a non-specific contrast agent. To date, clinical applications range from (i) angiography, intraoperative assessment of vessel patency, and tumor/metastasis delineation following intravenous administration of ICG, and (ii) imaging lymphatic architecture and function following subcutaneous and intradermal ICG administration. In the latter case, NIR fluorescence imaging may enable new discoveries associated with lymphatic function due to (i) a unique niche that is not met by any other conventional imaging technology and (ii) its exquisite sensitivity enabling high spatial and temporal resolution. Herein, we (i) review the basics of clinical NIR fluorescence imaging, (ii) survey the literature on clinical application of investigational devices using ICG fluorescent contrast, (iii) provide an update of non-invasive dynamic lymphatic imaging conducted with our FDPM device, and finally, (iv) comment on the future NIR fluorescence imaging for non-invasive and intraoperative use given recent demonstrations showing capabilities for imaging following microdose administration of contrast agent.

show abstract

Individualized surgery for early gastric cancer guided by sentinel node biopsy

Cited by 56 publications

References 17 publications

The accuracy of sentinel node mapping according to T stage in patients with gastric cancer

The accuracy of sentinel node mapping according to T stage in patients with gastric cancer

Sentinel Lymph Node Mapping of Invasive Urinary Bladder Cancer in Animal Models Using Invisible Light

Near-Infrared Fluorescence Imaging in Humans with Indocyanine Green: A Review and Update~!2009-12-07~!2009-12-23~!2010-05-26~!

Contact Info

Product

Resources

About